Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and doctors the…
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $530M
Founded date: 2018
Investors 6
| Date | Name | Website |
| 29.11.2022 | Foresite C... | foresiteca... |
| - | Longevity ... | longevity.... |
| - | OMX Ventur... | omx.vc |
| - | Altitude L... | altitudels... |
| - | Longevity ... | lvf.vc |
| 16.09.2024 | Catalio Ca... | cataliocap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.04.2022 | Series C | $300M | - |
| 12.01.2021 | Series B | $230M | - |
Mentions in press and media 11
| Date | Title | Description |
| 03.10.2024 | A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore | Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science... |
| 28.08.2024 | Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer | Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly c... |
| 06.08.2024 | Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner | Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that global... |
| 10.07.2024 | Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability | Record Year with Key Partnerships, Global Expansion and Expanded Top Talent CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has expanded its capital base by $3.6 bi... |
| 20.04.2022 | Venture capitalists just keep plowing billions into crypto startups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Oh hey. Declan Harty here today, filling in for Jessica. Today we’re diving into VC funding in wh... |
| 19.04.2022 | Tessera Therapeutics Raises Over $300M in Series C Financing | Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding. Investors included Abu Dhabi Investment Authority (ADIA), Alaska Permanent Fund Corporation, Altitude Life Science Ventures, ARTIS Ve... |
| 12.01.2021 | Tessera Therapeutics : Attracts Over $230M in Series B Financing to Advance ‘Gene Writing' – A New Category in Genetic Medicine | Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science... |
| 12.01.2021 | Daily funding roundup - January 12th, 2021 | Workato raised $110M;Landing landed $45M; Earli secured $40M; Descript picks up $30M Snowplow: Snowplow is a London-based behavioral data management platform. Snowplow has raised $10 million in Series A2 funding. Atlantic Bridge led the rou... |
| 12.01.2021 | Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure disease | Geoffrey von Maltzahn, Ph.D. (Flagship Pioneering) Move over, gene editing. There’s a new kid on the block. Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing... |
| 12.01.2021 | Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion | Technologists are getting better at coding biology and venture firms are flooding a new generation of startups with cash so they can commercialize their technology bringing in the next wave of genetic innovation. Tessera Therapeutics, the B... |
Show more